<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01542801</url>
  </required_header>
  <id_info>
    <org_study_id>SBP_prevention</org_study_id>
    <nct_id>NCT01542801</nct_id>
  </id_info>
  <brief_title>Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention</brief_title>
  <official_title>Comparison of Daily Norfloxacin Versus Weekly Ciprofloxacin for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sungkyunkwan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soon Chun Hyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  For the prevention of spontaneous bacterial peritonitis (SBP) in patients with liver
           cirrhosis, norfloxacin 400mg per day is a standard regimen.

        -  Ciprofloxacin 750 mg per week is also known to be effective for prevention of SBP. In
           addition, ciprofloxacin once weekly administration is more convenient and less costly.

        -  Therefore ciprofloxacin once weekly could be more useful if the the efficacy is
           comparable to norfloxacin once daily.

        -  This study aims to prove ciprofloxacin once weekly administration is as effective as
           norfloxacin once daily administration for the prevention of SBP in cirrhotic patients
           with ascites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spontaneous bacterial peritonitis (SBP) is one of the most serious complication of liver
      cirrhosis.

      The short term mortality reaches 20-30% mainly due to sepsis, hepatorenal syndrome, and liver
      failure. In addition, patients who suffered SBP show poor prognosis with 1 year-mortality of
      50-70%. The high recurrence rate is also problematic. Therefore appropriate prevention of SBP
      is critically needed to improve survival as well as quality of life.

      Selective intestinal decontamination (SID) is eradicating gram negative bacterial in the gut
      lumen, and effectively prevent development of SBP. Patients with gastrointestinal hemorrhage,
      low ascitic protein level, high bilirubin, or history of SBP need SID.

      Norfloxacin 400 mg daily administration decreased the incidence of SBP to 2% compared with
      17% of no prevention group's among patients with ascitic protein less than 1.5 g/dL. Also, in
      high risk patients (Child-Pugh score &gt; or = 9 points and serum bilirubin level &gt; or = 3
      mg/dL, serum creatinine level &gt; or = 1.2 mg/dL, blood urea nitrogen level &gt; or = 25 mg/dL, or
      serum sodium level &lt; or = 130 mEq/L), norfloxacin 400 mg/day improved 1 year-survival to 60%
      compared with 48% of no prevention group's. Therefore norfloxacin is now primarily recommend
      for the prevention of SBP in cirrhotic patients. However, norfloxacin should be administered
      on daily basis, so efforts to reduce cost and frequency have been made.

      Ciprofloxacin 750 mg weekly administration has been evaluated, and shown to be effective as
      3.6% versus 22% in prevention versus no prevention arm, respectively. Therefore,
      ciprofloxacin 750 mg/week is a reasonable option for prevention of SBP. However, comparison
      of efficacy of these two methods (norfloxacin 400 mg daily versus ciprofloxacin 750 mg
      weekly) has not been performed, yet.

      The investigators aim to compare the efficacy and safety of norfloxacin 400 mg daily and
      ciprofloxacin 750 mg weekly for the proper management of cirrhotic patients with ascites.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The prevention rate of spontaneous bacterial peritonitis (SBP)</measure>
    <time_frame>12 months</time_frame>
    <description>The incidence of SBP will measured in each the group. Thereby, prevention rate will also be compared between the groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1 year mortality</measure>
    <time_frame>12 months ( 1 year)</time_frame>
    <description>liver related mortality and overall mortality will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infectious event other than SBP</measure>
    <time_frame>12 months</time_frame>
    <description>Bacteremia, urinary tract infection, pneumonia, and other infections will be included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatorenal syndrome</measure>
    <time_frame>12 months</time_frame>
    <description>Diagnostic criteria of hepatorenal syndrome is defined by the latest version of Internation ascites club consensus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic encephalopathy</measure>
    <time_frame>12 months</time_frame>
    <description>Will follow the Western Heaven Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event of drugs</measure>
    <time_frame>12 months</time_frame>
    <description>Any of adverse event suspected by study drugs will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Adverse Reaction to Other Drugs and Medicines</condition>
  <arm_group>
    <arm_group_label>Norfloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>norfloxacin 400 mg once daily administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciprofloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciprofloxacin 750 mg per week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norfloxacin</intervention_name>
    <description>Norfloxacin 400 mg per day</description>
    <arm_group_label>Norfloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ciprofloxacin</intervention_name>
    <description>Ciprofloxacin 750 mg per week</description>
    <arm_group_label>Ciprofloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 20-75 years old

          -  Liver cirrhosis with ascites

          -  Ascitic polymorphonucleated cells (PMN) count &lt; 250/mm3

          -  Ascitic protein &lt;= 1.5 g/dL or History of SBP

        Exclusion Criteria:

          -  Incompatibility with inclusion criteria

          -  Hypersensitivity or intolerability with quinolones

          -  Hepatocellular carcinoma beyond Milan Criteria

          -  Hepatic encephalopathy over stage 2

          -  History of treatment with antibiotics within 2 weeks of enrollment

          -  HIV infection

          -  Untreated malignancy

          -  Women with child-bearing age not willing to use effective contraception.

          -  Pregnant or breast feeding women

          -  Not able to give informed consents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soon Ho Um, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyung Joon Yim, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University College of Medicine, Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University College of Medicine, Cheonan Hospital</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpuk National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University College of Medicine, Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sungkyunkwan University Gangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.lc-center.org/</url>
    <description>Liver cirrhosis clinical research center (PI of SBP_prevention study is belong to this center)</description>
  </link>
  <link>
    <url>http://www.korea.ac.kr</url>
    <description>Korea University (PI of SBP_prevention study is belong to this university)</description>
  </link>
  <reference>
    <citation>Mowat C, Stanley AJ. Review article: spontaneous bacterial peritonitis--diagnosis, treatment and prevention. Aliment Pharmacol Ther. 2001 Dec;15(12):1851-9. Review.</citation>
    <PMID>11736714</PMID>
  </reference>
  <reference>
    <citation>Koulaouzidis A, Bhat S, Karagiannidis A, Tan WC, Linaker BD. Spontaneous bacterial peritonitis. Postgrad Med J. 2007 Jun;83(980):379-83. Review.</citation>
    <PMID>17551068</PMID>
  </reference>
  <reference>
    <citation>Fernández J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo V, Rodés J. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002 Jan;35(1):140-8.</citation>
    <PMID>11786970</PMID>
  </reference>
  <reference>
    <citation>European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010 Sep;53(3):397-417. doi: 10.1016/j.jhep.2010.05.004. Epub 2010 Jun 1. Review.</citation>
    <PMID>20633946</PMID>
  </reference>
  <results_reference>
    <citation>Rolachon A, Cordier L, Bacq Y, Nousbaum JB, Franza A, Paris JC, Fratte S, Bohn B, Kitmacher P, Stahl JP, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology. 1995 Oct;22(4 Pt 1):1171-4.</citation>
    <PMID>7557868</PMID>
  </results_reference>
  <results_reference>
    <citation>Grangé JD, Roulot D, Pelletier G, Pariente EA, Denis J, Ink O, Blanc P, Richardet JP, Vinel JP, Delisle F, Fischer D, Flahault A, Amiot X. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J Hepatol. 1998 Sep;29(3):430-6.</citation>
    <PMID>9764990</PMID>
  </results_reference>
  <results_reference>
    <citation>Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, Pardo A, Quintero E, Vargas V, Such J, Ginès P, Arroyo V. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007 Sep;133(3):818-24. Epub 2007 Jul 3.</citation>
    <PMID>17854593</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2012</study_first_submitted>
  <study_first_submitted_qc>March 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2012</study_first_posted>
  <last_update_submitted>December 27, 2016</last_update_submitted>
  <last_update_submitted_qc>December 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University</investigator_affiliation>
    <investigator_full_name>Soon Ho Um</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Effect of Preventive Antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Norfloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

